NCT01900795终止2 期
A Phase 2a, Single-Center, Randomized, Double-Blind, Double- Dummy, Placebo- and Active-Controlled Analgesic Study of an Oral Dose of V117957 4.5 mg for the Treatment of Postsurgical Pain Due to Third Molar Extraction
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 114
- 试验地点
- 1
- 主要终点
- Total pain relief 0 to 8 hours after dosing (TOTPAR8)
研究概览
简要总结
The primary objective of this study is to assess the analgesic properties of an oral dose of V117957 4.5 mg aqueous suspension in the third molar extraction model
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 45 Years(Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
V117957
Experimental
干预措施: V117957 (Drug)
Ibuprofen
Active Comparator
干预措施: Ibuprofen (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Total pain relief 0 to 8 hours after dosing (TOTPAR8)
时间窗: 0 - 8 hours postdose
Time-weighted sum of pain relief scores 0 to 8 hours after dosing
次要结局
- Time to meaningful PR(Up to 24 hours postdose)
- Time to first use of rescue pain medication(Up to 24 hours postdose)
- Proportion of subjects taking rescue medication by time point(Up to 24 hours postdose)
- Global assessment of overall satisfaction(Hour 24 postdose)
- Total Pain Relief 0 - 4 hours after dosing (TOTPAR4)(Hour 4 postdose)
- Total Pain Relief 0 - 6 hours after dosing (TOTPAR6)(Hour 6 postdose)
- Total Pain Relief 0 - 12 hours after dosing (TOTPAR12)(Hour 12 postdose)
- Total Pain Relief 0 - 24 hours after dosing (TOTPAR24)(Hour 24 postdose)
- Pain Relief (PR) over time(Up to 24 hours postdose)
- Pain intensity difference over time(15, 30, 45 , 60, 90 minutes; 2, 3, 4, 4.5, 6, 8, 10, 12 and 24 hours postdose)
- Sum of pain intensity difference 0 to 4 hours after dosing (SPID4)(Hour 4 postdose)
- Sum of pain intensity difference 0 to 6 hours after dosing (SPID6)(Hour 6 postdose)
- Sum of pain intensity difference 0 to 8 hours after dosing (SPID8)(Hour 8 postdose)
- Sum of pain intensity difference 0 to 12 hours after dosing (SPID12)(Hour 12 postdose)
- Sum of pain intensity difference 0 to 24 hours after dosing (SPID24)(Hour 24 postdose)
- Time to first perceptible PR(Up to 24 hours postdose)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Postherpetic Neuralgia (PHN)PainPostherpetic NeuralgiaNCT01688947Purdue Pharma LP105
已完成
2 期
Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis (OA) of the KneePainOsteoarthritis, KneeNCT01688934Purdue Pharma LP230
已完成
2 期
A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Acute Vaginal Candidiasis (Yeast Infection)Candidiasis, VulvovaginalNCT01891331Viamet55
已完成
1 期
Study of V117957 in Overactive Bladder SyndromeOveractive Bladder SyndromeNCT06024642Imbrium Therapeutics51
已完成
1 期
Study of V117957 in Interstitial Cystitis/Bladder Pain SyndromeInterstitial Cystitis/Bladder Pain SyndromeNCT06285214Imbrium Therapeutics47
